Figure 5

Perp deficiency promotes mammary tumorigenesis. (A) Perp immunofluorescence on sections of mammary ducts from K14-Cre/+;Perp^fl/fl and control Perp^fl/fl female virgin mice. DAPI marks the nuclei. Arrows indicate cells exhibiting Perp loss. (B) Kaplan-Meier analysis graphing overall tumor-free survival, based on assessing all tumor types (breast, skin, and salivary gland tumors), in control K14-Cre/+;p53^fl/fl (n = 16; median survival, 265 days) and K14-Cre/+;p53^fl/fl;Perp^fl/+ (n = 16; median latency, 230 days) mice. P = 0.0224 by the Log-rank test. (C) Left, Graph depicting latency of all tumors identified in K14-Cre/+;p53^fl/fl (n = 36; mean tumor latency, 257.6 days) and K14-Cre/+;p53^fl/fl;Perp^fl/+ (n = 17; mean tumor latency, 224.4 days) mice by palpation. Significance (*) was determined by using an unpaired two-tailed t test, P = 0.0075. Right, Latency for mammary tumors detected by palpation is depicted for K14-Cre/+;p53^fl/fl (n = 12; mean tumor latency, 259 days) and K14-Cre/+;p53^fl/fl;Perp^fl/+(n = 6; mean tumor latency, 225 days) mice. Significance (*) was determined by using an unpaired two-tailed t test, P = 0.0228. (D) Representative H&E images demonstrating the range of differentiation states of mammary tumors observed in K14-Cre/+;p53^fl/fl and K14-Cre/+;p53^fl/fl;Perp^fl/+ mice. Images were taken at ×100 and ×400 magnification.